Lobe Sciences Expands Portfolio with Altemia® Acquisition
Company Announcements

Lobe Sciences Expands Portfolio with Altemia® Acquisition

Lobe Sciences Ltd (TSE:LOBE) has released an update.

Lobe Sciences Ltd. has successfully issued over 69 million common shares to acquire Altemia®, securing exclusive rights to utilize Altemia’s patented product formulations. As a result of the share issuance, Clearway Global, LLC now owns approximately 42% of Lobe Sciences and has become a deemed insider, also providing consulting services to the company. Lobe Sciences continues its commitment to developing innovative medicines for rare diseases and is involved in research with non-hallucinogenic psilocin-based compounds.

For further insights into TSE:LOBE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskLobe Sciences Launches Neurology Subsidiary Alera Pharma
TipRanks Canadian Auto-Generated NewsdeskLobe Sciences Announces Major Leadership Changes
TipRanks Canadian Auto-Generated NewsdeskLobe Sciences Ltd. Board Welcomes New Directors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App